Search Results | Blood | American Society of Hematology

1-20 of 178

2 3 4 5

Sort by

Sort Order Select

Journal Articles

PATCH trial: explanatory analyses

M. Irem Baharoglu, Rustam Al-Shahi Salman, Charlotte Cordonnier, Maria M. Koopman, Lynn Manson, Sophie Susen, Henk A. Marquering, Ludo F. Beenen, Charles B. Majoie, Yvo B. Roos

Blood (2020) 135 (16): 1406–1409.

DOI: https://doi.org/10.1182/blood.2019003298

Published: 2020

Includes: Supplemental data

Journal Articles

Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials

Jennifer A. Woyach

Blood (2019) 134 (21): 1796–1801.

DOI: https://doi.org/10.1182/blood.2019001321

Published: 2019

Journal Articles

Infection-Related Morbidity Reduced Overall Survival in a Large Real-World Cohort of Transplant Ineligible Newly Diagnosed Myeloma Patients Treated with UK Standard of Care

Faouzi Djebbari, Fotios Panitsas, Catherine Prodger, Fearn Davies, Kieran Burton, Akhil Khera, Grant Vallance, B.Sc., PhD, Sally Moore, Jaimal Kothari, Andy Peniket, MD, Karthik Ramasamy, MD PhD

Blood (2019) 134 (Supplement_1): 4768.

DOI: https://doi.org/10.1182/blood-2019-128139

Published: 2019

Journal Articles

Vascular and Parenchymal Alterations of the Liver and Liver Surveillance in Patients Who Received Inotuzumab Ozogamicin As the Standard of Care for Relapse/Refractory Acute Lymphoblastic Leukemia

Giovanni Marconi, Federico Ravaioli, MD, Giovanni Martinelli, MD, Elton Dajti, Maria Chiara Abbenante, MD, Chiara Sartor, MD, Luigina Vanessa Alemanni, MD, Jacopo Nanni, MD, Sarah Parisi, MD PhD, Giovanni Marasco, MD, Gianluca Cristiano, MD, Amanda Vestito, MD, Francesca Bonifazi, Stefania Paolini, MD PhD, Antonio Curti, MD PhD, Davide Festi, MD, Michele Cavo, Cristina Papayannidis, Antonio Colecchia, MD

Blood (2019) 134 (Supplement_1): 1343.

DOI: https://doi.org/10.1182/blood-2019-130632

Published: 2019

Journal Articles

Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories

Hagop M. Kantarjian, MD, Wendy Stock, MD, Ryan D. Cassaday, MD, Daniel J. DeAngelo, MD PhD, Elias Jabbour, MD, Susan M. O'Brien, MD, Matthias Stelljes, MD, Tao Wang, M. Luisa Paccagnella, Kevin Nguyen, Barbara Sleight, MD, Erik R. Vandendries, MD PhD, Alexander Neuhof, MD, A. Douglas Laird, PhD, Anjali S. Advani, MD

Blood (2019) 134 (Supplement_1): 1344.

DOI: https://doi.org/10.1182/blood-2019-122097

Published: 2019

Journal Articles

The Locommotion Study (MMY4001): A Prospective, Multinational Study of Real-Life Current Standards of Care in Patients with Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI, IMiD, and CD38 Monoclonal Antibody Treatment and Documented Disease Progression

Blood (2019) 134 (Supplement_1): 5549.

DOI: https://doi.org/10.1182/blood-2019-122939

Published: 2019

Journal Articles

Epidemiology of PNH and Real-World Treatment Patterns Following an Incident PNH Diagnosis in the US

Jessica J Jalbert, PhD, Umesh Chaudhari, MD, Haixin Zhang, MSc, Jonathan Weyne, MD, Jamile M. Shammo, MD

Blood (2019) 134 (Supplement_1): 3407.

DOI: https://doi.org/10.1182/blood-2019-125867

Published: 2019

Journal Articles

Dreamm-5: Platform Trial Evaluating Belantamab Mafodotin (a BCMA-directed Immuno-conjugate) in Combination with Novel Agents in Relapsed or Refractory Multiple Myeloma (RRMM)

Paul G. Richardson, MD, Swethajit Biswas, Beata Holkova, Nicola Jackson, Thelma Netherway, Weichao Bao, Geraldine Ferron-Brady, Anne Yeakey, Chris Shelton, Rocio Montes De Oca, PhD, Chris Ahlers, Sonia Franco, Marc Ballas, Elaine Paul, Katarina Luptakova, Ira Gupta, Joanna Opalinska

Blood (2019) 134 (Supplement_1): 1857.

DOI: https://doi.org/10.1182/blood-2019-129879

Published: 2019

Journal Articles

Effectiveness of Daratumumab in Combination with Lenalidomide and Dexamethasone (DRd) Vs. Common Standard-of-Care Regimens in Patients with Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM)

Brian G.M. Durie, MD, Shaji K. Kumar, MD, Saad Z. Usmani, MD, Bareng A.S. Nonyane, Eric A. Ammann, Annette Lam, Rachel Kobos, MD, Eric M Maiese, PhD, Thierry Facon, MD

Blood (2019) 134 (Supplement_1): 1830.

DOI: https://doi.org/10.1182/blood-2019-122937

Published: 2019

Journal Articles

Comparison of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) with Standard of Care for Patients from Latin America with Newly Diagnosed Multiple Myeloma (NDMM) Who Were Transplant Ineligible: A Propensity Score Matching Analysis

Vania T.M. Hungria, MD PhD, Deborah M. Martinez-Banos, Maria-Victoria Mateos, Meletios A. Dimopoulos, MD, Michele Cavo, Bart Heeg, PhD, Annette Lam, Gerardo Machnicki, Jianming He, PhD, Mariana Fernandez

Blood (2019) 134 (Supplement_1): 2143.

DOI: https://doi.org/10.1182/blood-2019-123557

Published: 2019

Journal Articles

Precision Medicine Treatment in Older AML: Results of Beat AML Master Trial

Blood (2019) 134 (Supplement_1): 175.

DOI: https://doi.org/10.1182/blood-2019-130201

Published: 2019

Journal Articles

Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium

Blood (2019) 134 (Supplement_1): 245.

DOI: https://doi.org/10.1182/blood-2019-129624

Published: 2019

Journal Articles

Cachexia at Diagnosis adversely predicts outcomes in patients with Aggressive B-Cell NHL receiving standard of care treatment: A Prospective Observational Study from India

Vivek S Radhakrishnan, MDDM,MSc, Reena Nair, MD, Anwesha Patra, Saurabh Jayant Bhave, MD, Jeevan Kumar Garg, MDDNB, Mohandas Mallath, MDDNB

Blood (2019) 134 (Supplement_1): 2907.

DOI: https://doi.org/10.1182/blood-2019-126295

Published: 2019

Journal Articles

Improved Overall Survival with Enasidenib Compared with Standard of Care Among Patients with Relapsed or Refractory Acute Myeloid Leukemia and IDH2 Mutations: A Propensity Score Matching Analysis Using Data from the AG221-C-001 Trial and Two Data Sources from France and Germany

Stephane De Botton, Joseph M Brandwein, MD, Eytan M. Stein, MD, Andrew H. Wei, Daniela Weber, Arnaud Pigneux, Nicolas Boissel, MD PhD, Peter Paschka, MD, Konstanze Döhner, Salem Abi Nehme, Mark G. Frattini, MD, Roland Marion-Gallois, Jixian (Jason) Wang, Chris Cameron, Muhaimen Siddiqui, Rana A. Qadeer, Hartmut Döhner

Blood (2019) 134 (Supplement_1): 3893.

DOI: https://doi.org/10.1182/blood-2019-122700

Published: 2019

Journal Articles

Is It Time to Take MRD More Seriously? Relationship between MRD, Functional Cure and Life Expectancy Among Patients with Ph- B Cell Precursor ALL (BCP-ALL)

Qiujun Shao, Simran Tiwana, Nicholas Despiegel, Franziska Dirnberger

Blood (2019) 134 (Supplement_1): 5814.

DOI: https://doi.org/10.1182/blood-2019-126309

Published: 2019

Journal Articles

Potential of 2018 ASH CLL Data to Alter Standard of Care for Initial CLL Treatment

Bruce A Feinberg, DO, Richard Sweat, PhD, Yolaine Jeune-Smith, PhD, Ajeet Gajra, MD FACP

Blood (2019) 134 (Supplement_1): 5816.

DOI: https://doi.org/10.1182/blood-2019-129029

Published: 2019

Journal Articles

Individualized Mitochondrial Functional Approach to Combination of BCL-2 and MCL-1 Antagonism in Acute Myeloid Leukemia

Shruti Bhatt, PhD, Marissa Pioso, Elyse Ann Olesinski, Binyam Yilma, Leutz Buon, Sophia Adamia, PhD, Holly Zhu, Jeremy Ryan, Youzhen Wang, Morris Erick, Ensar Halilovic, David M. Weinstock, MD, Jacqueline S Garcia, MD, Anthony Letai

Blood (2019) 134 (Supplement_1): 2551.

DOI: https://doi.org/10.1182/blood-2019-131101

Published: 2019

Journal Articles

Integration of Genetic, Transcriptomic, and Immune Profiles Reveals Genomically-Distinct Populations in Low-Grade Lymphomas

Keenan T. Hartert, PhD, Kerstin Wenzl, PhD, Jordan Krull, Michelle Manske, MS, BS, Vivekananda Sarangi, Melissa C Larson, Theodora Anagnostou, MD, Ellen D. McPhail, MD, Brian K. Link, MD, Stephen M Ansell, MD PhD, James R. Cerhan, MD PhD, Dragan Jevremovic, MD PhD, Anne J Novak, PhD

Blood (2019) 134 (Supplement_1): 2764.

DOI: https://doi.org/10.1182/blood-2019-128803

Published: 2019

Journal Articles

Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage IV Patients

Morie A Gertz, MD, Adam D. Cohen, MD, Raymond L Comenzo, MD, Charles Du Mond, Eftathios Kastritis, Heather J Landau, MD, Edward N. Libby, III, MD, Michaela Liedtke, MD, Giampaolo Merlini, MD, Vaishali Sanchorawala, MD, Stefan O. Schönland, MD, Ashutosh D Wechalekar, MBBS, MD FRCP, FRCPath, DM, Jeffrey A. Zonder, Gene Kinney, PhD

Blood (2019) 134 (Supplement_1): 3166.

DOI: https://doi.org/10.1182/blood-2019-124482

Published: 2019

Journal Articles

Stenosis Outcome at 1 and 3 Years after Transplantation Vs Standard-Care in Children with Sickle-Cell Anemia and Abnormal Transcranial Doppler with Stroke or No-Stroke History

Blood (2019) 134 (Supplement_1): 2271.

DOI: https://doi.org/10.1182/blood-2019-122699

Published: 2019

2 3 4 5

NARROW

PATCH trial: explanatory analyses

Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials

Infection-Related Morbidity Reduced Overall Survival in a Large Real-World Cohort of Transplant Ineligible Newly Diagnosed Myeloma Patients Treated with UK Standard of Care

Vascular and Parenchymal Alterations of the Liver and Liver Surveillance in Patients Who Received Inotuzumab Ozogamicin As the Standard of Care for Relapse/Refractory Acute Lymphoblastic Leukemia

Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories

Epidemiology of PNH and Real-World Treatment Patterns Following an Incident PNH Diagnosis in the US

Dreamm-5: Platform Trial Evaluating Belantamab Mafodotin (a BCMA-directed Immuno-conjugate) in Combination with Novel Agents in Relapsed or Refractory Multiple Myeloma (RRMM)

Effectiveness of Daratumumab in Combination with Lenalidomide and Dexamethasone (DRd) Vs. Common Standard-of-Care Regimens in Patients with Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM)

Comparison of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) with Standard of Care for Patients from Latin America with Newly Diagnosed Multiple Myeloma (NDMM) Who Were Transplant Ineligible: A Propensity Score Matching Analysis

Precision Medicine Treatment in Older AML: Results of Beat AML Master Trial

Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium

Cachexia at Diagnosis adversely predicts outcomes in patients with Aggressive B-Cell NHL receiving standard of care treatment: A Prospective Observational Study from India

Improved Overall Survival with Enasidenib Compared with Standard of Care Among Patients with Relapsed or Refractory Acute Myeloid Leukemia and IDH2 Mutations: A Propensity Score Matching Analysis Using Data from the AG221-C-001 Trial and Two Data Sources from France and Germany

Is It Time to Take MRD More Seriously? Relationship between MRD, Functional Cure and Life Expectancy Among Patients with Ph- B Cell Precursor ALL (BCP-ALL)

Potential of 2018 ASH CLL Data to Alter Standard of Care for Initial CLL Treatment

Individualized Mitochondrial Functional Approach to Combination of BCL-2 and MCL-1 Antagonism in Acute Myeloid Leukemia

Integration of Genetic, Transcriptomic, and Immune Profiles Reveals Genomically-Distinct Populations in Low-Grade Lymphomas

Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage IV Patients

Stenosis Outcome at 1 and 3 Years after Transplantation Vs Standard-Care in Children with Sickle-Cell Anemia and Abnormal Transcranial Doppler with Stroke or No-Stroke History

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only